In conclusion, aberrant activation of KP as well as a solid correlation between high expression of IDO1 or IDO1/TDO and tumor progression or poor patients’ outcome should be kept in mind when selecting the candidate tumor type for clinical trials of IDO1 inhibitors. Here, IDO1 is linked to neoplasm.